The spectrum of type III hyperlipoproteinemia

Fredrickson, 1967, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders, N Engl J Med, 276, 34, 10.1056/NEJM196701052760107 Morganroth, 1975, The biochemical, clinical, and genetic features of type III hyperlipoproteinemia, Ann Intern Med, 82, 158, 10.7326/0003-4819-82-2-158 Hopkins, 2014, Hyperlipoproteinemia type 3: the forgotten phenotype, Curr Atheroscler Rep, 16, 440, 10.1007/s11883-014-0440-2 Marais, 2014, Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E, Crit Rev Clin Lab Sci, 51, 46, 10.3109/10408363.2013.870526 Sniderman, 2007, Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B, J Clin Lipidol, 1, 256, 10.1016/j.jacl.2007.07.006 De Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias, Nat Clin Pract Endocrinol Metab, 4, 608, 10.1038/ncpendmet0982 Langlois, 2018, Quantifying atherogenic lipoproteins: current and future challenges in the Era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM, Clin Chem, 64, 1006, 10.1373/clinchem.2018.287037 Havel, 1955, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J Clin Invest, 34, 1345, 10.1172/JCI103182 Albers, 1978, Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein, Clin Chem, 24, 853, 10.1093/clinchem/24.6.853 LaRosa, 1986, Patterns of dyslipoproteinemia in selected North American populations. The lipid research clinics program prevalence study, Circulation, 73, I12 Hopkins, 2009, Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study, Atherosclerosis, 207, 559, 10.1016/j.atherosclerosis.2009.05.016 Hopkins, 2005, Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease, J Am Coll Cardiol, 45, 1003, 10.1016/j.jacc.2004.11.062 Evans, 2013, Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia, J Clin Lipidol, 7, 671, 10.1016/j.jacl.2013.05.003 Sniderman, 2008, Age as a modifiable risk factor for cardiovascular disease, Lancet, 371, 1547, 10.1016/S0140-6736(08)60313-X Nordestgaard, 2017, A test in context: lipid profile, fasting versus nonfasting, J Am Coll Cardiol, 70, 1637, 10.1016/j.jacc.2017.08.006